三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
Tarlatamab在PFS及癌症相关呼吸/咳嗽获益
Tarlatamab在PFS及癌症相关呼吸/咳嗽获益
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:355KB
图片尺寸:1155*700
同报告图片
/
4
fCBUaW1lIGZyb20gcmFuZG9taXphdGlvbiAobW9udGhzKSB8IFRhcmxhdGFtYWIgTnVtYmVyIG9mIHBhdGllbnRzIGF0IHJpc2sgfCBDaGVtb3RoZXJhcHkgTnVtYmVyIG9mIHBhdGllbnRzIGF0IHJpc2sgfCBQcm9ncmVzc2lvbi1mcmVlIFN1cnZpdmFsLCAlIChUYXJsYXRhbWFiKSB8IFByb2dyZXNzaW9uLWZyZWUgU3Vydml2YWwsICUgKENoZW1vdGhlcmFweSkgfAp8LS0tfC0tLXwtLS18LS0tfC0tLXwKfCAwIHwgMjU0IHwgMjU1IHwgMTAwIHwgMTAwIHwKfCAzIHwgMTQ3IHwgMTM3IHwgOTQgfCA5NCB8CnwgNiB8IDc4IHwgNTYgfCA4MCB8IDY5IHwKfCA5IHwgMzcgfCAxNSB8IDY1IHwgMzEgfAp8IDEyIHwgMTggfCAzIHwgNDcgfCAyMyB8CnwgMTUgfCAyIHwgMCB8IDMxIHwgMjAgfAp8IDE4IHwgMCB8IDAgfCAyMCB8IDQgfAoK6LWE5paZ5p2l5rqQ77yaTkVKTe+8jOS4nOWQtOivgeWIuOeglOeptuaJgA==
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
所属报告:
泽璟制药-公司研究报告-创新进入收获期ZG006及ZG005均有望成为BIC-250714(37页).pdf
打包全文图表
相关数据
依沃西为全球首个在三期临床中头对头击败K药的新药,PFS强阳性(HR=0.51)
收藏
行业数据
2026-03-31
原图定位
查看详情
HARMONi-6试验主要终点:依沃西+化疗较对照臂PFS提升4.2个月(HR=0.60)
收藏
行业数据
2026-03-31
原图定位
查看详情
CARTITUDE-4 TME: Patients With Shorter PFS (≤18M) and Patients With More pLOT had a More Suppressive TME
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
收藏
行业数据
2026-03-11
原图定位
查看详情
CARTITUDE-4: PFS and OS in Patients With Standard-Risk Cytogenetics (As-Treated)
fCDnu4TliKsgfCAzMOS4quaciOaXoOi/m+WxleeUn+WtmOeOh++8iFBGUywgJe+8iSB8IDMw5Liq5pyI5oC755Sf5a2Y546H77yIT1MsICXvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCBDQVJUSVRVREUgLSA0IOagh+WHhumjjumZqSB8IDgwLjUgfCA4Ny4zIHwKfCBDQVJUSVRVREUgLSA0IOagh+WHhumjjumZqSArIGdhaW4vYW1wKDFxKSB8IDcxLjcgfCA4Ni4xIHwKCui1hOaWmeadpea6kO+8mlBBUlRJVFVERSAtIDQg56CU56m277yI5qCH5YeG6aOO6Zmp57uG6IOe6YGX5Lyg5a2m5oKj6ICFIEFzIC0gVHJlYXRlZCDliIbmnpDvvInmlbDmja4=
收藏
行业数据
2026-03-11
原图定位
查看详情
Figure 3: PFS (A) and OS (B)
fCDmjIfmoIcgICAgICAgfCAzNuS4quaciOeOhyB8IDk1JSDnva7kv6HljLrpl7QgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18CnwgUEZTICAgICAgICB8IDkzLjglICAgIHwgNjMuMuKAkzk5LjEgICAgfAp8IE9TICAgICAgICAgfCA5My44JSAgICB8IDYzLjLigJM5OS4xICAgIHwKCui1hOaWmeadpea6kO+8muWbvueJh+S4reKAnFJlc3VsdHPigJ3mnb/lnZflj4pGaWd1cmUgM++8iFBGUyAoQSkg5ZKMIE9TIChCKe+8ieWGheWuueOAgg==
收藏
行业数据
2026-03-11
原图定位
查看详情
T-DXd对HER2-lowBC的全人群PFS
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
收藏
行业数据
2025-11-24
原图定位
查看详情
Ivonescimab国内临床,PFS显著优于K药
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
收藏
行业数据
2025-10-24
原图定位
查看详情
izabren展现EGFRmNSCLC二线治疗历史最长PFS(单位:月)
fCDmsrvnlpfmlrnmoYggICAgICAgfCBQRlPvvIjmnIjvvIkgfAp8LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLXwKfCBJWkEgLSBCUkVOICAgICB8IDEyLjUgICAgICB8CnwgU0tCMjY0ICAgICAgICAgfCAxMS41ICAgICAgfAp8IEFCQ1AgICAgICAgICAgIHwgOS43ICAgICAgIHwKfCBBSzExMiArIGNoZW1vICB8IDcuNiAgICAgICB8CnwgU0JDUCAgICAgICAgICAgfCA3LjIgICAgICAgfAp8IEhlcjMgLSBkeGQgICAgIHwgNS44ICAgICAgIHwKfCBEYXRvICAgICAgICAgICB8IDUuNCAgICAgICB8CgrotYTmlpnmnaXmupDvvJrljLvoja/prZTmlrnmlbDmja7lupPvvIzlm73ms7DmtbfpgJror4HliLjnoJTnqbbvvJvms6jvvJpTS0IyNjQg5pWw5o2u5p2l6IeqIDIwMjQgQUFDUjs=
收藏
行业数据
2025-09-16
原图定位
查看详情
Vepdegestrantvs氟维司群在HR+/HER2-BC(全人群)的PFS数据
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
收藏
行业数据
2025-08-08
原图定位
查看详情
R/RCLL最新PFS数据支持BGB-16673开展与匹妥布替尼的头对头试验
fCDpobnnm64gfCBCR0ItMTY2NzMgfCDljLnlronluIPmm7/lsLwgfAp8LS0tLS0tfC0tLS0tLS0tLS18LS0tLS0tLS0tLXwKfCBuICAgIHwgNjYgICAgICAgfCAxMTkgICAgICB8Cnwg5Lit5L2NUEZTLCDmnIggKDk1JSBDSSkgfCAyMi44ICgxNS42KSB8IDE0LjAgKDExLjItMTYuNikgfAp8IOS4reS9jemaj+iuv+aXtumXtCwg5pyIIHwgMTUuNiAgICAgIHwgMTkuNCAgICAgIHw=
收藏
行业数据
2025-08-07
原图定位
查看详情
CELESTIAL-301临床:全球唯一旨在证明相比目前固定疗程标准疗法具有PFS
fCDliIblsYLlm6DntKAgfCBB57uEIHwgQue7hCB8CnwtLS0tLS0tLS0tLXwtLS0tLXwtLS0tLXwKfCDlubTpvoQoPDY15bKB5a+55q+U4omlNjXlsoEpIHwgICAgIHwgICAgIHwKfCBJR0hWKOeqgeWPmOWvueavlOacqueqgeWPmCkgfCAgICAgfCAgICAgfAp8IOaYr+WQpuS8tOaciTE3cOe8uuWksS9UUDUz56qB5Y+YIHwgICAgIHwgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuOa8lOekuuadkOaWme+8jOWbvemHkeivgeWIuOeglOeptuaJgA==
收藏
行业数据
2025-08-07
原图定位
查看详情
无明确驱动基因NSCLC(无论PD-L1表达状态),依沃西PFS数据佳,SSGJ-707的ORR及安全性佳
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
收藏
行业数据
2025-07-17
原图定位
查看详情
戈利昔替尼与西达本胺的PFS曲线对比
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
收藏
行业数据
2025-06-23
原图定位
查看详情
外显子21(L858R)和外显子19缺失亚组PFS率对比
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
收藏
行业数据
2025-06-09
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
他山之石:塔拉妥单抗于 2025ASCO 大会上口头报告其Ⅲ期临床结果,显示 OS 获益。针对 DeLLphi-304 临床试验(多国、III 期、开放标签的临床试验,比较 Tarlatamab与化疗在小细胞肺癌患者中作为二线治疗的效果),共有 509 名患者被随机分配至Tarlatamab 组(254 人)或化疗组(255 人)。Tarlatamab 显著延长了患者的总生存期(中位 OS 为 13.6 个月,化疗组为 8.3 个月;分层死亡风险比为 0.60;95%置信区间为 0.47至 0.77;P<0.001)。与化疗相比,Tarlatamab 在无进展生存期及癌症相关的呼吸困难和咳嗽方面也表现出显著获益。3 级及以上不良事件的发生率在 Tarlatamab 组低于化疗组(54%vs.80%),因不良事件导致停药的发生率也较低(5%vs.12%)。
行业数据
原图定位
当前图表所属:
泽璟制药-公司研究报告-创新进入收获期ZG006及ZG005均有望成为BIC-250714(37页).pdf
自免疾病具备广阔的临床应用和市场潜力
PD-1/TIGIT药物主要进展(截至2025H1)
CD3/DLL3主要相关药物临床进展(截至2025H1)
小细胞肺癌免疫治疗专家共识(2025版)要点
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》